Atrasentan
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anum Ijaz M.B.B.S., M.D.[2]
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
EMBRYO-FETAL TOXICITY
See full prescribing information for complete Boxed Warning.
EMBRYO-FETAL TOXICITY
|
Overview
Atrasentan is an endothelin receptor antagonist that is FDA approved for the treatment of in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include peripheral edema and anemia (incidence >5%)..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
FDA-labeled Indications
- VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
- This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
Dosage Information
Recommended Dosage
- The recommended dose of VANRAFIA is 0.75 mg administered orally once daily with or without food.
- Swallow tablets whole. Do not cut, crush, or chew.
- If a dose or doses are missed, take the prescribed dose at the next scheduled time.
- Do not double the dose to make up for a missed dose.
Dosage Forms and Strengths
- VANRAFIA 0.75 mg: film-coated, round, biconvex, white to off-white tablet debossed with “7” on one side and unmarked on the other side.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Atrasentan in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Atrasentan in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Atrasentan FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Atrasentan in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Atrasentan in pediatric patients.
Contraindications
- Pregnancy
Use of VANRAFIA is contraindicated in patients who are pregnant.
- Hypersensitivity
VANRAFIA is contraindicated in patients with a history of a hypersensitivity reaction to atrasentan or any component of the product.
Warnings
|
EMBRYO-FETAL TOXICITY
See full prescribing information for complete Boxed Warning.
EMBRYO-FETAL TOXICITY
|
Embryo-Fetal Toxicity
- Based on data from animal reproduction studies, VANRAFIA may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy.
- The available human data for endothelin receptor antagonists do not establish the presence or absence of major birth defects related to the use of VANRAFIA.
- Counsel patients who can become pregnant of the potential risk to a fetus. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise patients to use effective contraception prior to initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with VANRAFIA.
- When pregnancy is detected, discontinue VANRAFIA as soon as possible.
Hepatotoxicity
- Some endothelin receptor antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. Asymptomatic and transient transaminase elevations have been observed with VANRAFIA.
- Obtain liver enzyme testing before initiating VANRAFIA and repeat during treatment as clinically indicated. In patients with elevated aminotransferases at baseline (>3 × upper limit of normal [ULN]), consider periodic liver test monitoring.
- Do not initiate VANRAFIA in patients with severe hepatic impairment.
- Advise patients to report symptoms suggesting hepatic injury (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching).
- If clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin >2 x ULN, or by clinical symptoms of hepatotoxicity, discontinue VANRAFIA.
- Consider re-initiation of VANRAFIA when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity or jaundice.
Fluid Retention
- Fluid retention may occur with ERAs and has been observed in clinical studies with VANRAFIA.
- VANRAFIA has not been evaluated in IgAN patients with heart failure. If clinically significant fluid retention develops, consider initiating or increasing diuretic treatment and interrupting VANRAFIA treatment.
Decreased Sperm Counts
- VANRAFIA, similar to other ERAs, may have an adverse effect on spermatogenesis. Counsel men about potential effects on fertility.
Adverse Reactions
Clinical Trials Experience
Clinical Trials Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- The safety of VANRAFIA was evaluated in ALIGN (NCT04573478), a randomized, double-blind, placebo controlled clinical study in 403 adults with IgAN. The median duration of treatment was 47 weeks (range: 0 to 128 weeks).
- The most common adverse reactions (≥ 5%) with VANRAFIA were peripheral edema and anemia. Table 1 describes the adverse reactions that occurred in ≥ 2% of patients treated with VANRAFIA and higher than placebo in the ALIGN study.
Laboratory Tests and Vital Signs
Hemoglobin Decrease
- At Week 36, the mean change in hemoglobin from baseline for those patients receiving VANRAFIA in the ALIGN study was -0.7 g/dL compared to -0.2 g/dL for those receiving placebo.
- The incidence of a hemoglobin decrease > 2 g/dL compared to baseline and below the lower limit of normal was greater for the VANRAFIA arm (12%) compared to the placebo arm (4%).
- These decreases are thought to be in part due to hemodilution. There were no treatment discontinuations due to anemia or hemoglobin decrease in the ALIGN study.
Blood Pressure Decrease
- At Week 36, the mean change from baseline in systolic and diastolic blood pressure (BP) for patients receiving VANRAFIA in the ALIGN study was -4 mmHg and -4 mmHg, respectively, compared to +3 mmHg and +2 mmHg, respectively, in patients receiving placebo.
- Hypotension observed in VANRAFIA treated patients was mild or moderate in severity, rarely symptomatic, and did not necessitate treatment discontinuation.
Postmarketing Experience
There is limited information regarding Atrasentan Postmarketing Experience in the drug label.
Drug Interactions
Effect of Other Drugs n VANRAFIA
Strong or Moderate CYP3A Inducers
- Avoid concomitant use with a strong or moderate CYP3A inducer.
- Atrasentan is a CYP3A substrate.
- Concomitant use with a strong and moderate CYP3A inducer is expected to decrease atrasentan exposure.
OATP1B1/1B3 Inhibitors
- Avoid concomitant use with organic anion transporting polypeptides 1B1/1B3 (OATP1B1/1B3) inhibitors.
- Atrasentan is a OATP1B1/1B3 substrate.
- Concomitant use with a OATP1B1/1B3 inhibitor increases atrasentan exposure which may increase the risk of VANRAFIA adverse reactions.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): Risk Summary
- Based on data from animal reproductive toxicity studies, VANRAFIA may cause fetal harm, including birth defects and fetal death, when administered to a pregnant patient and is contraindicated during pregnancy.
- There are no available data on VANRAFIA use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
- Available data from published literature and post-marketing surveillance over decades of use with products in the same pharmacologic class (ERA) have not identified an increased risk of major birth defects. However, these data are limited and do not establish the presence or absence of a drug-associated risk of major birth defects.
- Methodological limitations of these post marketing reports and published literature include lack of a control group; limited information regarding dose, duration, and timing of exposure; and missing data.
- These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal endothelin receptor antagonist use.
- In animal reproduction studies, oral administration of atrasentan to pregnant rats and rabbits throughout organogenesis at doses that were below the maximum recommended human dose (MRHD) based on area under the curve (AUC) caused teratogenic effects in rats and rabbits (see Data). Advise pregnant patients of the potential risk to the fetus.
- The background risk of major birth defects and miscarriage for the indicated population is unknown.
- All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
- In embryo-fetal development studies in pregnant rats and rabbits, teratogenicity and/or embryo-fetal toxicity were observed.
- In pregnant rats, oral administration of atrasentan throughout organogenesis at doses of 0.1, 0.3, 1.0, and 3.0 mg/kg/day resulted in developmental abnormalities primarily including the ear, lower jaw, or skull in all treated groups with detectable plasma exposures to atrasentan.
- The no adverse effect level of atrasentan plasma exposure was not determined. * In pregnant rabbits, oral administration of atrasentan throughout organogenesis at doses of 0.1, 0.3, 1.0 and 3.0 mg/kg/day resulted in visceral malformations including deformities in the cardiovascular system in all atrasentan-treated groups. The lowest detectable plasma exposures to atrasentan were approximately 0.2 times the AUC at the MRHD.
- In the pre- and postnatal development study in rats, atrasentan was orally administered to pregnant rats at doses of 1, 10, or 100 mg/kg/day during the period from gestation Day 15 through lactation Day 20. No adverse effects on pre- and postnatal development were observed at doses up to 10 mg/kg/day which resulted in maternal exposure approximately 55 times the AUC at the MRHD. Higher exposure to atrasentan (dose of 100 mg/kg/day) increased pup mortality during the pre-weaning period, and increased heart weight which correlated histologically with myocardial hypertrophy.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Atrasentan in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Atrasentan during labor and delivery.
Nursing Mothers
Risk Summary
- There are no data on the presence of atrasentan in human milk, the effects on the breastfed infant, or the effect on milk production.
- Because of the potential for adverse reactions, such as fluid retention in breastfed infants, advise patients not to breastfeed during treatment with VANRAFIA.
Pediatric Use
The safety and efficacy of VANRAFIA in pediatric patients have not been established.
Geriatic Use
- There were 29 (7%) patients 65 years of age and older in the ALIGN study of VANRAFIA. Of the total number of VANRAFIA-treated patients, 15 (7%) were 65 years to 75 years of age, and 3 (2%) were 75 years of age and older.
- No overall differences in safety and effectiveness were observed between these patients and younger patients.
Gender
There is no FDA guidance on the use of Atrasentan with respect to specific gender populations.
Race
There is no FDA guidance on the use of Atrasentan with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Atrasentan in patients with renal impairment.
Hepatic Impairment
- No dose adjustment is required for patients with mild or moderate hepatic impairment.
- Do not initiate VANRAFIA in patients with severe hepatic impairment.
Females of Reproductive Potential and Males
Based on data from animal reproductive toxicity studies, VANRAFIA may cause fetal harm, including birth defects and fetal death, when administered to a pregnant patient and is contraindicated during pregnancy.
- Pregnancy Testing
Exclude pregnancy before initiating VANRAFIA in females of reproductive potential. The patient should contact their physician immediately for pregnancy testing if onset of menses is delayed or pregnancy is suspected. If pregnancy is confirmed, the physician should discuss with the patient the risks to the pregnancy and the fetus.
- Contraception
Patients who can become pregnant while using VANRAFIA should use effective contraception prior to initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with VANRAFIA to prevent pregnancy.
- Infertility
Decreased sperm counts have been observed in some patients with diabetic kidney disease (DKD) receiving VANRAFIA 0.75 mg once daily with return to normal levels within approximately 3 months after drug discontinuation. This effect has not been studied in patients with IgAN.
Immunocompromised Patients
There is no FDA guidance one the use of Atrasentan in patients who are immunocompromised.
Administration and Monitoring
Administration
- Swallow tablets whole. Do not cut, crush, or chew.
- If a dose or doses are missed, take the prescribed dose at the next scheduled time.
- Do not double the dose to make up for a missed dose.
Monitoring
There is limited information regarding Atrasentan Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Atrasentan and IV administrations.
Overdosage
- There is no experience with overdose of VANRAFIA.
- Atrasentan has been given in a single dose up to 139.5 mg and multiple doses up to 40 mg/day in healthy volunteers. Overdose of VANRAFIA may result in headache or vasodilation.
- In the event of an overdose, standard supportive measures should be taken, as required. Dialysis is unlikely to be effective because atrasentan is highly protein-bound.
Pharmacology
There is limited information regarding Atrasentan Pharmacology in the drug label.
Mechanism of Action
Atrasentan is an ETA receptor antagonist (Ki = 0.034 nM) with >1800-fold selectivity for the ETA receptor compared to the endothelin type B receptor (Ki = 63.3 nM). Endothelin (ET)-1 is thought to contribute to the pathogenesis of IgAN via the ETAR.
Structure
VANRAFIA contains atrasentan, an endothelin type A (ETA) receptor antagonist. The chemical name of atrasentan hydrochloride is (2R, 3R, 4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid hydrochloride. Atrasentan hydrochloride has a molecular weight of 547.09 g/mol, a molecular formula of C29H38N2O6HCl and the following structural formula.
Add vanrafia structure
Pharmacodynamics
- Dose-response information is not available. At the recommended dose regimen, no statistically significant exposure-response (E-R) relationship was identified between atrasentan exposure and the percentage reduction from baseline in UPCR at Week 36 over the observed atrasentan exposure range.
- Increased atrasentan exposure was associated with an increased incidence of anemia, but no association was observed between atrasentan exposure and hypotension or peripheral edema.
Cardiac Electrophysiology At exposures 40% higher than the clinical exposure at the maximum recommended dose, clinically significant QTc interval prolongation was not observed.
Pharmacokinetics
- Atrasentan area under the time concentration curve (AUC) is dose proportional across the 0.35 mg to 30 mg (0.47 to 40 times the approved recommended dosage) dose range. Atrasentan steady state plasma concentrations are reached within 7 days with 2- to 3-fold accumulation.
- Absorption
Atrasentan time to peak plasma concentration (Tmax) is approximately 0.5 hour.
- Effect of Food
No clinically significant differences in atrasentan pharmacokinetics were observed following administration with a high-fat meal (800 to 1000 Kcal, > 50% fat) in healthy subjects.
- Distribution
Atrasentan steady-state apparent (oral) volume of distribution (Vd/F) is 1180 L. Atrasentan is > 99% bound to human plasma proteins, in vitro.
- Elimination
Atrasentan effective half-life is approximately 24 to 41 hours with an apparent (oral) clearance (CL/F) of 19 L/h.
- Metabolism
Atrasentan is extensively metabolized by CYP3A and multiple uridine 5'-diphospho-glucuronosyltransferases (UGTs) with approximately half via CYP3A and the remaining half via glucuronidation by multiple UGTs.
- Excretion
After a single dose of radiolabeled atrasentan 10 mg to healthy subjects, approximately 86% of the dose was recovered in feces (5.5% as parent atrasentan). Renal excretion was minimal, with < 4% recovered in urine (negligible amounts of parent atrasentan).
- Specific Populations
No clinically significant differences in the pharmacokinetics of atrasentan were observed based on age (19 to 77 years), sex, race, mild to severe renal impairment (eGFR 15 to 90 mL/min/1.73 m2, estimated by CKD-EPI), or mild to moderate hepatic impairment (Child-Pugh class A or B). The effect of severe hepatic impairment (Child-Pugh class C) or end-stage renal disease (eGFR < 15 mL/min/1.73 m2) on atrasentan pharmacokinetics is unknown.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
- In female rats orally administered atrasentan for 2 years, no atrasentan-related tumor findings were observed at exposures approximately 12 times the AUC at the MRHD.
- At a higher exposure (approximately 24 times the AUC at the MRHD, or 2 mg/kg/day), an increased incidence of benign uterine stromal polyps considered of low human relevance was observed.
- In male rats, no carcinogenic effects were observed at exposures approximately 100 times the AUC at the MRHD.
- There were no atrasentan-related tumor findings observed in male and female transgenic mice administered atrasentan for 6 months at doses up to 60 mg/kg/day.
Mutagenesis
- There was no evidence of mutagenicity or clastogenicity for atrasentan in in vitro bacteria reverse mutation and chromosomal aberration assays, or in an in vivo mouse micronucleus study.
Impairment of Fertility
- In a fertility study, male rats were treated with atrasentan at doses of 5, 20, and 60 mg/kg/day and mated with untreated female rats.
- No adverse effects on male fertility were observed at 5 mg/kg/day, approximately 53 times the AUC at the MRHD.
- At higher doses, decreased numbers of implantation sites, reduced viable fetuses, and increased pre-implantation loss were observed in the untreated female rats mated with the treated male rats. These effects were reversible at 20 mg/kg/day, approximately 422 times the AUC at MRHD.
- In rats and dogs, testicular degeneration, dilatation of seminiferous tubules, interstitial edema of the testes, and prostate inflammation were observed at all doses tested, and a no adverse effect dose level could not be determined.
- In a female rat fertility study, no reproductive toxicity was observed following oral administration during premating, mating, and early gestation at doses up to 100 mg/kg/day.
- In female rats, cystic endometrial hyperplasia was observed at the lowest dose tested of 0.8 mg/kg/day.
Clinical Studies
IgA Nephropathy
- The effect of VANRAFIA on proteinuria was assessed in a randomized, double-blind, placebo-controlled, multicenter, global study (ALIGN, NCT04573478) in adults with biopsy-proven primary IgAN, an eGFR ≥ 30 mL/min/1.73 m2, and urine protein ≥ 1 g/day on a stable dose of maximally tolerated renin angiotensin system inhibitor.
- The study included two cohorts: a main cohort of 340 patients and an exploratory cohort of 64 patients who were also on a stable dose of sodium glucose co-transporter 2 inhibitor (SGLT2i) at baseline.
- Patients with chronic kidney disease due to another condition in addition to IgAN or those who had been recently treated with systemic immunosuppressants were excluded. Patients were randomized (1:1) to receive either VANRAFIA 0.75 mg or placebo once daily. RAS inhibitor therapy was continued throughout the study. Rescue immunosuppressive treatment could be initiated per investigator discretion during the trial.
- The efficacy analysis included the first 270 patients in the main cohort who reached the Week 36 visit. At baseline, the mean age was 45 years (range: 19 to 77 years); 59% were male, 36% White, 57% Asian, 2% Black or African American and 5% other or not specified. At baseline, 60% had a history of hypertension, 1.5% had a history of type 2 diabetes, and 45% had hematuria based on urine dipstick. The mean baseline eGFR was 59 mL/min/1.73 m2.
- The geometric mean baseline UPCR was 1.5 g/g sampled from a 24-hour urine and 15% of patients had proteinuria > 3.5 g/day.
- The adjusted geometric mean percent change from baseline in UPCR over time is displayed in Figure on right.
- The treatment effect on UPCR at Week 36 was consistent across subgroups including age, sex, race, baseline disease characteristics (such as baseline eGFR and proteinuria levels) within the main cohort.
- The treatment effect on UPCR at Week 36 was also consistent in the exploratory SGLT2i cohort.
How Supplied
VANRAFIA is supplied as follows:
- 0.75 mg tablets are film-coated, round, biconvex, white to off-white tablets debossed with “7” on one side and unmarked on the other side, packaged in a high-density polyethylene (HDPE) bottle containing a desiccant, with induction seal and child-resistant cap. Each bottle contains 30 tablets (NDC 0078-1420-15).
Storage
- Store at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F).
Images
Drug Images
{{#ask: Page Name::Atrasentan |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Atrasentan |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling (Medication Guide)
Embryo-Fetal Toxicity
- Educate and counsel female patients of reproductive potential to use effective contraception prior to starting treatment with VANRAFIA, during treatment and for two weeks after treatment discontinuation.
- Patients who can become pregnant should have a negative pregnancy test prior to treatment with VANRAFIA.
- Patients should be instructed to immediately contact their physician if they suspect they may be pregnant.
- Patients should seek additional contraceptive advice as needed.
- Educate and counsel patients who can become pregnant on the use of emergency contraception in the event of unprotected sex or contraceptive failure.
- Advise patients to contact their healthcare provider if they want to change the form of birth control which is used to ensure that another acceptable form of birth control is selected.
Hepatotoxicity
- Some members of this pharmacological class are hepatotoxic.
- Educate patients on signs of hepatotoxicity. Advise patients that they should contact their doctor if they have unexplained nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching.
Fluid Retention
- Educate patients on signs of fluid retention. Advise patients that they should contact their doctor if they have unusual weight increase or swelling of the ankles or legs.
Lactation
- Advise patients not to breastfeed during treatment with VANRAFIA.
- Other Risks Associated with VANRAFIA
- Instruct patients that the risks associated with VANRAFIA also include decreases in sperm count
Precautions with Alcohol
Alcohol-Atrasentan interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Atrasentan Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Atrasentan Look-Alike Drug Names in the drug label.
Price
References
The contents of this FDA label are provided by the National Library of Medicine.